|
1
|
Gaughan EM and Costa DB: Genotype-driven
therapies for non-small cell lung cancer: Focus on EGFR, KRAS and
ALK gene abnormalities. Ther Adv Med Oncol. 3:113–125. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Rosell R, Carcereny E, Gervais R, et al
Spanish Lung Cancer Group in collaboration with Groupe Français de
Pneumo-Cancérologie and Associazione Italiana Oncologia Toracica:
Erlotinib versus standard chemotherapy as first-line treatment for
European patients with advanced EGFR mutation-positive
non-small-cell lung cancer (EURTAC): A multicentre, open-label,
randomised phase 3 trial. Lancet Oncol. 13:239–246. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Takano T, Ohe Y, Sakamoto H, et al:
Epidermal growth factor receptor gene mutations and increased copy
numbers predict gefitinib sensitivity in patients with recurrent
non-small-cell lung cancer. J Clin Oncol. 23:6829–6837. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kobayashi S, Boggon TJ, Dayaram T, et al:
EGFR mutation and resistance of non-small-cell lung cancer to
gefitinib. N Engl J Med. 352:786–792. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kosaka T, Yatabe Y, Endoh H, et al:
Analysis of epidermal growth factor receptor gene mutation in
patients with non-small cell lung cancer and acquired resistance to
gefitinib. Clin Cancer Res. 12:5764–5769. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Riely GJ, Kris MG, Rosenbaum D, et al:
Frequency and distinctive spectrum of KRAS mutations in never
smokers with lung adenocarcinoma. Clin Cancer Res. 14:5731–5734.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
De Luca A and Normanno N: Predictive
biomarkers to tyrosine kinase inhibitors for the epidermal growth
factor receptor in non-small-cell lung cancer. Curr Drug Targets.
11:851–864. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Mao C, Qiu LX, Liao RY, et al: KRAS
mutations and resistance to EGFR-TKIs treatment in patients with
non-small cell lung cancer: A meta-analysis of 22 studies. Lung
Cancer. 69:272–278. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Pao W, Wang TY, Riely GJ, et al: KRAS
mutations and primary resistance of lung adenocarcinomas to
gefitinib or erlotinib. PLoS Med. 2:e172005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Stella GM, Scabini R, Inghilleri S, et al:
EGFR and KRAS mutational profiling in fresh non-small cell lung
cancer (NSCLC) cells. J Cancer Res Clin Oncol. 139:1327–1335. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Pennycuick A, Simpson T, Crawley D, et al:
Routine EGFR and KRAS Mutation analysis using COLD-PCR in non-small
cell lung cancer. Int J Clin Pract. 66:748–752. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hammerman PS, Jänne PA and Johnson BE:
Resistance to epidermal growth factor receptor tyrosine kinase
inhibitors in non-small cell lung cancer. Clin Cancer Res.
15:7502–7509. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lynch TJ, Bell DW, Sordella R, et al:
Activating mutations in the epidermal growth factor receptor
underlying responsiveness of non-small-cell lung cancer to
gefitinib. N Engl J Med. 350:2129–2139. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Sequist LV, Martins RG, Spigel D, et al:
First-line gefitinib in patients with advanced non-small-cell lung
cancer harboring somatic EGFR mutations. J Clin Oncol.
26:2442–2449. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Paez JG, Jänne PA, Lee JC, et al: EGFR
mutations in lung cancer: Correlation with clinical response to
gefitinib therapy. Science. 304:1497–1500. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Cortes-Funes H, Gomez C, Rosell R, et al:
Epidermal growth factor receptor activating mutations in Spanish
gefitinib-treated non-small-cell lung cancer patients. Ann Oncol.
16:1081–1086. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Tanaka T, Matsuoka M, Sutani A, et al:
Frequency of and variables associated with the EGFR mutation and
its subtypes. Int J Cancer. 126:651–655. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Mitsudomi T, Morita S, Yatabe Y, et al
West Japan Oncology Group: Gefitinib versus cisplatin plus docetaxel
in patients with non-small-cell lung cancer harbouring mutations of
the epidermal growth factor receptor (WJTOG3405): An open label,
randomised phase 3 trial. Lancet Oncol. 11:121–128. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Mok TS, Wu YL, Thongprasert S, et al:
Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N
Engl J Med. 361:947–957. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Rosell R, Viteri S, Molina MA, et al:
Epidermal growth factor receptor tyrosine kinase inhibitors as
first-line treatment in advanced nonsmall-cell lung cancer. Curr
Opin Oncol. 22:112–120. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Pao W and Chmielecki J: Rational,
biologically based treatment of EGFR-mutant non-small-cell lung
cancer. Nat Rev Cancer. 10:760–774. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yun CH, Mengwasser KE, Toms AV, et al: The
T790M mutation in EGFR kinase causes drug resistance by increasing
the affinity for ATP. Proc Natl Acad Sci USA. 105:2070–2075. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yip PY, Yu B, Cooper WA, et al: Patterns
of DNA mutations and ALK rearrangement in resected node negative
lung adenocarcinoma. J Torac Oncol. 8:408–414. 2013. View Article : Google Scholar
|
|
24
|
Ding L, Getz G, Wheeler DA, et al: Somatic
mutations affect key pathways in lung adenocarcinoma. Nature.
455:1069–1075. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Shigematsu H, Lin L, Takahashi T, et al:
Clinical and biological features associated with epidermal growth
factor receptor gene mutations in lung cancers. J Natl Cancer Inst.
97:339–346. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Tam IY, Chung LP, Suen WS, et al: Distinct
epidermal growth factor receptor and KRAS mutation patterns in
non-small cell lung cancer patients with different tobacco exposure
and clinicopathologic features. Clin Cancer Res. 12:1647–1653.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Schmid K, Oehl N, Wrba F, et al:
EGFR/KRAS/BRAF mutations in primary lung adenocarcinomas and
corresponding locoregional lymph node metastases. Clin Cancer Res.
15:4554–4560. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Linardou H, Dahabreh IJ, Kanaloupiti D, et
al: Assessment of somatic k-RAS mutations as a mechanism associated
with resistance to EGFR-targeted agents: A systematic review and
meta-analysis of studies in advanced non-small-cell lung cancer and
metastatic colorectal cancer. Lancet Oncol. 9:962–972. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Misale S, Yaeger R, Hobor S, et al:
Emergence of KRAS mutations and acquired resistance to anti-EGFR
therapy in colorectal cancer. Nature. 486:532–536. 2012.PubMed/NCBI
|
|
30
|
Diaz LA Jr, Williams RT, Wu J, et al: The
molecular evolution of acquired resistance to targeted EGFR
blockade in colorectal cancers. Nature. 486:537–540.
2012.PubMed/NCBI
|
|
31
|
Parsons BL and Myers MB: Personalized
cancer treatment and the myth of KRAS wild-type colon tumors.
Discov Med. 15:259–267. 2013.PubMed/NCBI
|
